143 related articles for article (PubMed ID: 15468973)
1. Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases.
Ishida A; Kanoh K; Nishisaka T; Miyazu Y; Iwamoto Y; Kohno N; Miyazawa T
Intern Med; 2004 Aug; 43(8):718-20. PubMed ID: 15468973
[TBL] [Abstract][Full Text] [Related]
2. Effect of gefitinib on brain metastases from non-small cell lung cancer.
Nishi N; Kawai S; Yonezawa T; Fujimoto K; Masui K
Neurol Med Chir (Tokyo); 2006 Oct; 46(10):504-7. PubMed ID: 17062991
[TBL] [Abstract][Full Text] [Related]
3. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
Zeng YD; Zhang L; Liao H; Liang Y; Xu F; Liu JL; Dinglin XX; Chen LK
Asian Pac J Cancer Prev; 2012; 13(3):909-14. PubMed ID: 22631670
[TBL] [Abstract][Full Text] [Related]
5. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.
Gurpide A; Perez-Gracia JL; Lopez-Picazo JM; Moreno M; Zubieta JL; Martin-Algarra S; Garcia-Foncillas J
Clin Lung Cancer; 2005 Sep; 7(2):138-40. PubMed ID: 16179102
[TBL] [Abstract][Full Text] [Related]
6. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
8. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
9. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
Fang L; Sun X; Song Y; Zhang Y; Li F; Xu Y; Ma S; Lin N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):873-7. PubMed ID: 26310285
[TBL] [Abstract][Full Text] [Related]
10. [Gefitinib in the treatment of advanced non-small cell lung cancer].
Yang L; Liu XY; Fang J; An TT; Wu MN
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):474-7. PubMed ID: 17152500
[TBL] [Abstract][Full Text] [Related]
11. Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.
Mochizuki S; Nishimura N; Inoue A; Murakami K; Nukiwa T; Chohnabayashi N
Respir Investig; 2012 Sep; 50(3):117-21. PubMed ID: 23021771
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
13. Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Chonan M; Narita N; Tominaga T
BMC Res Notes; 2016 Jan; 9():2. PubMed ID: 26724810
[TBL] [Abstract][Full Text] [Related]
14. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
[TBL] [Abstract][Full Text] [Related]
15. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
Kim YH; Mio T; Mishima M
Intern Med; 2009; 48(18):1677-9. PubMed ID: 19755773
[TBL] [Abstract][Full Text] [Related]
17. Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.
Katz A; Zalewski P
Br J Cancer; 2003 Dec; 89 Suppl 2(Suppl 2):S15-8. PubMed ID: 14661048
[TBL] [Abstract][Full Text] [Related]
18. Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report.
Stemmler HJ; Weigert O; Krych M; Schoenberg SO; Ostermann H; Hiddemann W
Anticancer Drugs; 2005 Aug; 16(7):747-9. PubMed ID: 16027524
[TBL] [Abstract][Full Text] [Related]
19. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
[TBL] [Abstract][Full Text] [Related]
20. Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Walther JC; Khorshid M; Gaya A; Plowman PN
Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):637-9. PubMed ID: 17051957
[No Abstract] [Full Text] [Related]
[Next] [New Search]
